Sydney Institute for Infectious Diseases webinar recording now available: JEV outbreak in Australia - important insight for clinicians
A recording of the Sydney Institute for Infectious Diseases webinar: JEV outbreak in Australia - important insight for clinicians is now available.
The Australasian Society of Infectious Diseases (ASID) and Australian and New Zealand Association of Neurologists (ANZAN) welcomed a panel of expert speakers to discuss the current JEV outbreak in Australia on Thursday 17 March.
To access the recording, please click on the link below:
For additional information regarding JEV, please refer to our MVEC reference page:
Vocal cord dysfunction/inducible laryngeal obstruction(s) mimicking anaphylaxis during SARS-CoV-2 (COVID-19) vaccination
Researchers at Monash Health have published findings related to vocal cord dysfunction/inducible laryngeal obstruction(s) (VCD/ILO) in relation to incident-associated VCD which may be related to vaccination.
Their findings are related to a case series of ten individuals who were initially labelled as having experienced anaphylaxis following COVID-19 vaccination. These individuals were referred on to a specialist allergy service, where 9 out of the 10 received a second dose of the same COVID-19 vaccine that caused their initial reaction. It was found that 2 out of the 10 individuals met the Brighton Criteria for anaphylaxis, and symptoms recurred in 8 of the 9 individuals who received a second dose, mirroring their initial reactions which had been diagnosed as anaphylaxis.
Clinical features of VCD/ILO overlap with those of the Brighton Criteria for vaccine-related anaphylaxis, with this research demonstrating the need for providers to be able to differentiate between anaphylaxis and VCD/ILO.
To read the article in full, please follow the link below:
过敏和临床免疫学杂志：声带功能障碍/诱导性喉阻塞模仿 SARS-CoV-2 (COVID-19) 疫苗接种期间的过敏反应
For further information on how to differentiate between anaphylaxis and an acute stress response, refer to the animation on the MVEC：过敏和免疫 reference page.
The Conversation: Flu, COVID and flurona: what we can and can’t expect this winter
With international borders open and public health measures alleviated, it is highly likely that COVID-19 and influenza will be circulating simultaneously in Australian communities this coming winter.
This article addresses some probable outcomes and provides helpful tips on how people can protect themselves during this flu season.
Click on the link below to read the full article:
Flu, COVID and flurona: what we can and can’t expect this winter
《纽约时报》：在非洲，多种枪击事件推动了不确定的新冠疫苗接种进程
尽管许多富裕国家在使用辉瑞和 Moderna 疫苗进行 COVID-19 加强疫苗接种方面进展顺利，但非洲国家仍然依赖许多研究人员认为会降低疫苗功效的产品和给药方案。
整个非洲大陆的新冠疫苗接种率平均约为 14%，专家透露，疫苗接种存在一些需要考虑的障碍，并警告第五波可能更致命的浪潮即将到来。
请点击以下链接阅读全文：
《纽约时报》：在非洲，多种枪击事件推动了不确定的新冠疫苗接种进程
CDC: Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years
A recent study conducted by the CDC and the VISION Network examined 39,217 emergency department (ED), urgent care (UC) encounters and 1,699 hospitalisations among persons aged 5 to 17 years with COVID-19–like illness during April 9, 2021–January 29, 2022. The study employed a case-control test-negative design to estimate the VE of two doses of the Pfizer-BioNTech vaccine in preventing COVID-19 associated hospitalisations in this cohort.
Click on the link below to access the study findings:
CDC: Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort
The CDC has released the findings of a recent PROTECT study, assessing the efficacy of two doses of Pfizer-BioNTech vaccine in preventing infection from the Omicron variant amongst children 5 to 11 and adolescents 12 to 15 years of age. The study included clinical data from a cohort of 1,364 participants gathered from July 2021 to February 2022.
The report provides evidence that two doses of the Pfizer-BioNTech vaccine is effective in preventing both asymptomatic and symptomatic SARS-CoV-2 infection in this cohort.
Click on the link below to read the full report:
New global vaccine trial launched to evaluate fractional COVID-19 booster shots
CEPI will provide up to AU $12.3 million to support a global clinical trial led by the Murdoch Children’s Research Institute (MCRI) on the potential merits of administering a reduced COVID-19 booster dose. The trial which will include up to 3300 healthy adults across Australia, Indonesia and Mongolia coincides with a large-scale global initiative to increase access to COVID-19 vaccines.
“Our project, announced today with CEPI, will specifically examine how best to vaccinate communities with follow-up booster shots and the timings around these subsequent booster doses. And while fractional doses could provide the opportunity for great savings for countries, they are also likely to produce less side effects, which will improve the acceptability of booster doses” MCRI’s Professor Kim Mulholland.
A similar strategy, known as fractionation has previously been used to maximize global vaccine supply during outbreaks of Yellow fever, Polio and most recently, for the experimental rotavirus vaccine.
To fund this important work, CEPI’s Global Pandemic Preparedness Summit will take place next month, bringing together leading figures from across the world to work on this urgent global health initiative.
要阅读全文，请点击以下链接：
New global vaccine trial launched to evaluate fractional COVID-19 booster shots
ATAGI 关于 COVID-19 疫苗接种错误的临床指南
ATAGI has provided the below guidance for clinicians outlining the appropriate management of common COVID-19 vaccine administration errors. It includes scenarios where the vaccine is administered in the following circumstances:
- Via the incorrect site/route
- At a higher/lower dose
- Following incorrect storage and handling
- In an unapproved age group
- Mixed vaccine schedules
- With incorrect intervals
It is important to note that in Victoria, any vaccine administration error should be reported to 赛维克. Following the identification of a vaccine error, open disclosure with the vaccine recipient is important and addressing the cause of the error will prevent errors from occurring again in the future.
To read the full guideline, follow the link below:
New resource: NCIRS Decision aid (5–15 years): Should I get the COVID-19 vaccine for my child?
NCIRS have designed a new decision aid resource to help families make an informed decision about whether COVID-19 vaccination is right for their children.
The tool provides evidence-based information about the disease and the vaccine and takes the user through five simple steps to help weigh up the risks and benefits of vaccination.
To access the decision guide, please click on the link below.
New resource: NCIRS Decision aid (5–15 years): Should I get the COVID-19 vaccine for my child?
COVID-19 疫苗的临床建议 - 更新的加强建议
澳大利亚免疫技术咨询小组 (ATAGI) 提供了关于使用加强剂量的 COVID-19 疫苗的最新建议：
- 建议 18 岁及以上的个人接受单次加强剂量的任一 mRNA 疫苗（辉瑞公司 或者 现代), 初级疫苗接种完成后 3 个月。
- 建议 16-17 岁的个人在完成主要课程后 3 个月接受单剂 Comirnaty（辉瑞）作为他们的助推器。其他 COVID-19 疫苗品牌未注册用作该年龄段的加强剂量。
- 同时 Nuvaxovid (Novavax) 未在 TGA 注册用作加强剂量，ATAGI 建议在存在 mRNA 疫苗禁忌症的情况下，可将其用作 18 岁或以上个人的加强剂。支持使用 Nuvaxovid 作为加强剂量的安全性和有效性数据有限，但没有理论上的担忧。
- Vaxzevria（阿斯利康） 不再推荐用作加强剂量。已经接受 Vaxzevria（阿斯利康）作为加强剂的个人不需要重复服用替代品牌的加强剂。
有关 ATAGI 关于使用加强剂量的 COVID-19 疫苗的建议的更多信息，请参阅以下链接：
ATAGI 关于使用加强剂量的 COVID-19 疫苗的建议